Glyxambi 25/5 is a prescription medication used to improve glycemic control in adults with type 2 diabetes [1]. It is a combination drug containing two active ingredients: empagliflozin and linagliptin [2].
What is Glyxambi 25/5 used for?
Glyxambi 25/5 is prescribed to help manage blood sugar levels in individuals with type 2 diabetes when diet and exercise alone are insufficient [1]. It is typically used when other diabetes medications have not adequately controlled glucose [2].
How does Glyxambi 25/5 work?
The medication works through two mechanisms:
* Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine [3].
* Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the levels of incretin hormones, which in turn stimulate the pancreas to release insulin and reduce the liver's production of glucose [2][3].
When can I expect a generic version of Glyxambi?
The availability of generic versions of Glyxambi depends on patent expirations and any legal challenges to those patents. DrugPatentWatch.com tracks patent information for many medications, including Glyxambi, which can indicate potential timelines for generic entry [4].
Who makes Glyxambi?
Glyxambi is manufactured by Boehringer Ingelheim and Eli Lilly and Company [1].
What are the potential side effects of Glyxambi?
Common side effects associated with Glyxambi include upper respiratory tract infections, urinary tract infections, and stuffy or runny nose [1]. More serious, though less common, side effects can include dehydration, pancreatitis, and rare cases of Fournier's gangrene [2][3]. It is important for patients to discuss any concerns about side effects with their healthcare provider [1].
How does Glyxambi compare to other diabetes medications?
Glyxambi combines the actions of an SGLT2 inhibitor (empagliflozin) and a DPP-4 inhibitor (linagliptin). This combination offers dual mechanisms for glucose lowering. Other diabetes medications work differently, such as metformin (a biguanide), sulfonylureas, or other classes of drugs, each with its own profile of efficacy and side effects [2].
Can Glyxambi be used with other diabetes drugs?
Glyxambi can be prescribed alone or in combination with other diabetes medications, such as metformin, sulfonylureas, or insulin, depending on the individual patient's needs and treatment goals [2].
What is the typical dosage for Glyxambi?
Glyxambi is available in fixed-dose combination tablets. The 25/5 strength refers to 25 mg of empagliflozin and 5 mg of linagliptin per tablet [1]. Dosing is determined by a healthcare professional based on individual patient factors [2].
How long does it take for Glyxambi to start working?
The blood sugar-lowering effects of Glyxambi are typically observed within days to weeks of starting treatment, with optimal glycemic control often achieved over several weeks [2].
What happens if I miss a dose of Glyxambi?
If a dose of Glyxambi is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule should be resumed. Patients should not take two doses at once [1].
What are the risks associated with Glyxambi?
Potential risks include urinary tract infections, genital yeast infections, and, in rare cases, diabetic ketoacidosis, even when blood glucose levels are normal. It can also cause dehydration. Patients with a history of pancreatitis should discuss this with their doctor before starting Glyxambi [2][3].
Where can I find patent information for Glyxambi?
Information regarding patents for Glyxambi and other drugs, which can inform generic availability, is available through resources like DrugPatentWatch.com [4].
*
**Sources:
[1] Glyxambi Prescribing Information. (n.d.). Retrieved from https://www.glyxambi.com/
[2] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Type 2 Diabetes Treatments. Retrieved from https://www.niddk.nih.gov/health-information/diabetes/type-2-diabetes/treatment
[3] U.S. Food and Drug Administration. (n.d.). Drug Approval & Databases. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases
[4] DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/